Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Uesaka K, et al. Among authors: ojima h. Lancet. 2016 Jul 16;388(10041):248-57. doi: 10.1016/S0140-6736(16)30583-9. Epub 2016 Jun 2. Lancet. 2016. PMID: 27265347 Clinical Trial.
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K, Kuwano H, Ojima H, Otsuji T, Kato T, Shimada K, Hyodo I, Nishina T, Shirao K, Esaki T, Ohishi T, Denda T, Takeuchi M, Boku N. Yamazaki K, et al. Among authors: ojima h. Cancer Chemother Pharmacol. 2015 Mar;75(3):569-77. doi: 10.1007/s00280-015-2676-0. Epub 2015 Jan 10. Cancer Chemother Pharmacol. 2015. PMID: 25575764 Clinical Trial.
Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T, Shimada Y, Mizusawa J, Kinugasa Y, Kanemitsu Y, Ohue M, Fujii S, Takiguchi N, Yatsuoka T, Takii Y, Ojima H, Masuko H, Kubo Y, Mishima H, Yamaguchi T, Bando H, Sato T, Kato T, Nakamura K, Fukuda H, Moriya Y. Hamaguchi T, et al. Among authors: ojima h. Lancet Gastroenterol Hepatol. 2018 Jan;3(1):47-56. doi: 10.1016/S2468-1253(17)30297-2. Epub 2017 Oct 24. Lancet Gastroenterol Hepatol. 2018. PMID: 29079411 Clinical Trial.
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T; JASPAC 01 Study Group. Hagiwara Y, et al. Among authors: ojima h. Eur J Cancer. 2018 Apr;93:79-88. doi: 10.1016/j.ejca.2018.01.081. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29477795 Clinical Trial.
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, Nagasaka T, Hatano E, Ojima H, Manaka D, Kusumoto T, Katayose Y, Fujiwara T, Yoshida K, Unno M, Hyodo I, Tomita N, Sugihara K, Maehara Y. Oki E, et al. Among authors: ojima h. Br J Cancer. 2019 Jul;121(3):222-229. doi: 10.1038/s41416-019-0518-2. Epub 2019 Jul 9. Br J Cancer. 2019. PMID: 31285591 Free PMC article. Clinical Trial.
Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial.
Kanemitsu Y, Shitara K, Mizusawa J, Hamaguchi T, Shida D, Komori K, Ikeda S, Ojima H, Ike H, Shiomi A, Watanabe J, Takii Y, Yamaguchi T, Katsumata K, Ito M, Okuda J, Hyakudomi R, Shimada Y, Katayama H, Fukuda H; JCOG Colorectal Cancer Study Group. Kanemitsu Y, et al. Among authors: ojima h. J Clin Oncol. 2021 Apr 1;39(10):1098-1107. doi: 10.1200/JCO.20.02447. Epub 2021 Feb 9. J Clin Oncol. 2021. PMID: 33560877 Free PMC article. Clinical Trial.
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.
Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M. Kakeji Y, et al. Among authors: ojima h. Gastric Cancer. 2022 Jan;25(1):188-196. doi: 10.1007/s10120-021-01224-2. Epub 2021 Aug 5. Gastric Cancer. 2022. PMID: 34351555 Clinical Trial.
Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Tsutsumi S, Ishibashi K, Uchida N, Ojima H, Hosouchi Y, Yashuda N, Kigure W, Yamauchi S, Asao T, Ishida H, Kuwano H. Tsutsumi S, et al. Among authors: ojima h. Oncology. 2012;83(3):151-7. doi: 10.1159/000337992. Epub 2012 Aug 7. Oncology. 2012. PMID: 22889925 Clinical Trial.
339 results